Biocon Ltd (BIOCON) — shareholding pattern, promoter holding, financials and share price

About Biocon Ltd (BIOCON)

Biocon Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BIOCON and on the BSE under scrip code 532523. Its ISIN is INE376G01013.

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Biocon is a fully integrated, innovation‑led biopharmaceutical company from India focused on biosimilars, complex biologics, interchangeable insulins, generic formulations, peptides (GLP‑1s) and research/CRDMO services through Syngene with global manufacturing and commercialization reach across North America, Europe and emerging markets.

The group is at an operational inflection: major capex is largely complete, operating leverage is beginning to play out, and management highlights margin expansion and cash‑flow led value creation as priorities while retaining significant R&D investment of about INR 249 crore in Q3 FY26.

Listed peers in Pharmaceuticals: Aurobindo Pharma Ltd, Laurus Labs Ltd, Alkem Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Abbott India Ltd, Ipca Laboratories Ltd.

Valuation & Returns

10 Jul 2026

At ₹418.95 a share on 10 Jul 2026, Biocon Ltd (BIOCON) was valued at a price-to-earnings ratio of 185.13x against an industry P/E of 36.41x and a price-to-book of 3.15x on a book value of ₹132.81 per share as of Mar 2025. Solomo computes return on equity of 1.7% and return on capital employed of 3.59% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
185.13x
Industry P/E
36.41x
P/B
3.15x
EPS (TTM)
₹2.26
Book value / share
₹132.81
ROE
1.7%
ROCE
3.59%
ROA
0.63%
Debt / equity
0.85x
Dividend yield
0.12%
EBITDA margin
20.23%
52-week range
₹331 – ₹440.3

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Biocon Ltd (BIOCON) reported revenue of ₹16,927 crore, net profit of ₹369 crore and earnings per share of ₹2.38. That compares with revenue of ₹15,262 crore and net profit of ₹1,429 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹4,517 crore and net profit ₹199 crore (consolidated).

Consolidated annual results for Biocon Ltd (BIOCON), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)8,18411,17414,75615,26216,927
Net profit (₹ cr)7726431,2981,429369
EPS (₹)5.43.858.528.442.38
Compound annual growth for Biocon Ltd (BIOCON). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth-0.45%2.44%8.86%3.43%
Profit growth5.74%6.91%91.99%10.14%
Stock price CAGR14%1%19%12%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 44.68% of Biocon Ltd (BIOCON) (down 0.23 pp QoQ), foreign institutional investors (FII) hold 8.14% and domestic institutional investors (DII) hold 23.38%. Market capitalisation was ₹68,276 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2004.

Largest disclosed public shareholders in Jun 2026: MAGNUM HYBRID LONG SHORT FUND 8.75%, MYLAN INC. 5.64%, LIFE INSURANCE CORPORATION OF INDIA 3.73%, SERUM INSTITUTE LIFE SCIENCES PRIVATE LIMITED 3.4%, ISIF EQUITY EX-TOP 100 LONG-SHORT FUND 1.46%, KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK NIFTY MIDC 1.29%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202644.68%-8.14%23.38%55.27%
Mar 202644.91%-7.52%24.07%55%
Dec 202554.45%-7.39%21.71%45.43%
Sep 202554.45%-6.61%22.1%45.41%
Jun 202554.45%-6.04%22.82%45.37%
Mar 202560.64%-5.66%15.72%39.15%
Dec 202460.64%-5.66%15.37%39.14%
Sep 202460.64%-5.93%14.44%39.12%
Every quarter since Jun 2004 Filing data, not investment advice.